Postoperative Noninvasive Ventilation After Upper Abdominal Surgery in Chronic Obstructive Lung Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Luxor, Egypt, 85951
- asmaa Mostafa
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Age˃18 years, scheduled for upper abdominal surgery under general anesthesia.
- Moderate to very severe COPD (GOLD II to IV).
- ASA functional status II or greater.
Exclusion criteria:
- Contraindications to the application of NIV.
- Sleep apnea syndrome.
- Facial deformation.
- Inability to follow the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group N
50 patients.NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
|
NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
|
|
No Intervention: group C
50 patients recieved conventional oxygen therpy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
acute respiratory events
Time Frame: 28days
|
patients %
|
28days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
acute respiratory failure
Time Frame: 28 days
|
patients %
|
28 days
|
|
intubation rate
Time Frame: 28 days
|
patients %
|
28 days
|
|
ICU mortality
Time Frame: 28 days
|
patients %
|
28 days
|
|
ICU length of stay
Time Frame: 28 days
|
days
|
28 days
|
|
infectious and non infectious complications
Time Frame: 28 days
|
patients %
|
28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NIV _COPD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.